OBJECTIVES: The objective of this cost study was to measure the resource utilisation and the direct costs associated with health-care management of metastatic malignant melanoma (mMM) in Slovakia and provide a basis for cost-effectiveness evaluations.  METHODS: The cross-sectional survey was performed and included 3 oncologists experienced in mMM management. The survey was performed to obtain the information on the management of patients with mMM and to estimate the direct costs of the disease. The studied population were 3 cohorts of mMM patients which are usually identified as the health states in the cost-effectiveness models: “Before progression“,  “Disease progression“ and “Terminal care“. Costs of drugs were assesed separately from health states and rated particularly according to BRAF positivity. The cost data were assessed for the year 2013. All types of health care used in mMM management were evaluated (outpatient and inpatient visits, diagnostics, prescription drugs and medical examinations). Costs of adverse events (AEs) were set for one single event.  RESULTS: The most frequent treatment regimens used in the first treatment line of BRAF mutant and BRAF negative patients were identical - dacarbazin (94.9% of treated patients), fotemustin (4.5%) and ipilimumab (0.6%). Monthly costs of mMM management in addition to the active treatment in the state “Before progression“ count for 6.64% (€188.51/patient), during the “Disease progression“ it was 45.56% (€1 294.31/patient) and during the “Terminal state of patient“ 47.80% (€1 358.02/patient). Adverse event (AE) costs were evaluated for grade 3 and 4. The most costly AEs were neutropenia (€1 014.66), fever (€364.87) and rash (€230.35).  CONCLUSIONS : In the management of mMM (excluding the active drug cost), the most expensive are the costs of hospitalization and symptomatic treatment. The most costly period is the “Terminal state“.